<DOC>
	<DOCNO>NCT01495962</DOCNO>
	<brief_summary>Damage control laparotomy ( DCL ) life save maneuver use success trauma acute general surgery patient . The technique involve source control sepsis hemorrhage abbreviate laparotomy . In word , surgical procedure cut short allow resuscitation ICU immediately life threaten pathology treat . Planned re-exploration performed within 24-48 hour . It procedure injury reconstruct . This technique , unfortunately , several complication implicit use include wound infection , enterocutaneous fistula formation , intra-abdominal abscess development . [ 1 ] Additionally , patient primary fascial closure achieve , extensive abdominal wall reconstruction require 6-12 month . The key preventing complication definitive closure abdominal fascia , however , 10-50 % patient plan ventral hernia open abdominal wound dismissal [ 1,2 ] Proven method decrease rate plan ventral hernia utilize tension midline counter effect lateral abdominal muscular retraction . [ 3,4,5 ] Despite improvement , however , plan ventral hernia rate continue substantial . [ 2 ] Botulinum toxin ( BTX ) FDA approve neuron modulate agent use extensively cosmetic , motor pain disorder past 20 year [ 6,7 ] . The toxin block acetylcholine pain modulator release ( calcitonin gene relate peptide substance P ) pre-synaptic cholinergic nerve terminal . The peptide unable bind motor end plate receptor process cleaves protein involve transport protein cascade . This result flaccid paralysis neuromodulation abdominal wall muscle result reduced lateral tension pain . Theoretically , could increase rate primary fascial closure , improve pain sensation , decrease rate complication associate open abdomen lower cost need future abdominal wall reconstruction .</brief_summary>
	<brief_title>The Biomechanical Effects Flaccid Paralysis Induced Botulinum Toxin After Damage Control Laparotomy</brief_title>
	<detailed_description />
	<mesh_term>Paralysis</mesh_term>
	<mesh_term>Abdominal Injuries</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Inclusion Criteria male female , age â‰¥ 18 year old sign Informed Consent form appropriate patient representative undergone DCL trauma acute general surgery Exclusion Criteria death prior BTX injection failure achieve hemodynamic stability within 24 hour ( stable decreasing vasopressor support within 6 hour combination stable improve base deficit lactate level ) Viable pregnancy At risk population ( &lt; 18 year age , prisoner ) BMI &gt; 50 Preexisting pareses ( Amyotrophic Lateral Sclerosis , myopathy , motor polyneuropathies impair neuromuscular transmission ( Myasthenia Gravis , LambertEaton Syndrome ) concurrent aminoglycoside use chronic obstructive pulmonary disease know metastatic malignancy preexist cirrhosis necrotizing fasciitis trunk hypocoagulable state ( INR &gt; 1.5 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Damage Control Laparotomy</keyword>
	<keyword>Open Abdomen</keyword>
	<keyword>Botulinum Toxin A</keyword>
	<keyword>Primary Fascial Closure</keyword>
</DOC>